Follow-up study on ThinPrep cytology test-positive patients in tropical regions

Table 1 Changes in ThinPrep cytology test and human papillomavirus genotyping of the 10 patients who were followed up for 5 consecutive years

No.	Age	2011 TCT	2011 Biopsy	2011 HPV genotyping	2012 TCT	2012 HPV genotyping	2013 TCT	2013 HPV genotyping	2014 TCT	2014 HPV genotyping	2015 TCT	2015 HPV genotyping	2018 Biopsy
1	33	ASC-US	0	0	ASC-H	0	AGC-NOS	All negative	LSIL	0	AGC-NOS	0
2	47	ASC-US	0	0	ASC-US	0	ASC-US	All negative	AGC-NOS	All negative	AGC-NOS	All negative
3	20	ASC-US	0	0	AGC-NOS	0	ASC-H	16, 18, 43	AGC-NOS	All negative	AGC-NOS	16
4	43	ASC-US	0	51, 43, 52	AGC-NOS	0	AGC-NOS	All negative	AGC-NOS	0	AGC-NOS	52, 53, 59
5	41	ASC-US	0	0	AGC-NOS	All negative	AGC-NOS	All negative	AGC-NOS	5, 11	LSIL	All negative
6	46	LSIL	0	2	ASC-H	0	AGC-NOS	0	AGC-NOS	0	AGC-NOS	0
7	38	LSIL	NILM	0	ASC-US	0	AGC-NOS	All negative	AGC-NOS	0	AGC-NOS	All negative
8	36	LSIL	NILM	0	AGC-NOS	0	HSIL	58	AGC-NOS	8	AGC-NOS	53, 56, 81
9	40	LSIL	NILM	16	AGC-NOS	16	AGC-NOS	58	AGC-NOS	0	AGC-NOS	All negative	LSIL
10	27	LSIL	LSIL	0	AGC-NOS	0	AGC-NOS	0	AGC-NOS	0	AGC-NOS	All negative

AGC-NOS: Atypical glandular cells not otherwise specified; ASC-H: Atypical squamous cells highly indicating the existence of high-grade cervical lesions; ASC-US: Atypical squamous cells of undetermined significance; HPV: Human papillomavirus; HSIL: High-grade squamous intraepithelial lesions; LSIL: Low-grade squamous intraepithelial lesions; NILM: Negative for intraepithelial lesion or malignancy; TCT: ThinPrep cytology test.